Answers are grounded in this paper and cite their sources.
Methodological protocol demonstrates reliable autoantibody profiling in cancer patients, highlighting practical approaches to monitor tumor-specific humoral immunity.
With the identification of tumor antigens, the host immune response to various types of cancers can now be studied with a high degree of specificity in large cohorts of patients, in the hope of correlating immunity with clinical events and defining immunotherapeutic strategies. Several antigens, such as NY-ESO-1, p53, or SOX2, have attracted attention because of their frequent spontaneous immunogenicity in cancer patients, notably in their ability to induce humoral responses. We describe in this chapter a simple implementation of a serological monitoring platform for autoantibody measurement in cancer patients, from production of recombinant antigens to ELISA testing and interpretation.
No takes yet. Share an insight, caveat, or question.
Gnjatic et al. (2009) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: